Key Takeaways
- GHK-Cu is not an FDA-approved drug. It is sold legally as a cosmetic ingredient in topical products, while injectable GHK-Cu is unapproved and available only through compounding pharmacies.
- Typical dosing protocols for GHK-Cu are not standardized, but research suggests topical applications.
- Titration schedules are crucial for optimizing efficacy and minimizing side effects.
- Administration is primarily topical, with specific guidelines for application frequency and duration.
- Medical supervision is essential to tailor dosing to individual needs and monitor for adverse effects.
What Is GHK-Cu (Copper Peptide)?
GHK-Cu is a naturally occurring tripeptide-copper complex studied for its role in extracellular matrix regulation, redox homeostasis, and tissue remodeling. While its therapeutic potential is promising, it is currently available only for research purposes and is not FDA-approved for clinical use. For more detailed information, visit the GHK-Cu full profile.
GHK-Cu Dosage Chart
Two entirely different dosing conversations get filed under "GHK-Cu dosage", and mixing them up is the most common source of confusion. Topical dosing is measured as a percentage concentration in a cream or serum. Injectable dosing is measured in milligrams. They are not convertible, and the evidence behind them is not comparable.
| Route | Typical amount | Frequency | Evidence behind it |
|---|---|---|---|
| Topical serum or cream | 0.05%-2% GHK-Cu by concentration | Once or twice daily | Cosmetic formulation practice, supported by skin-regeneration research[1] |
| Subcutaneous injection | 1-2 mg | Once daily, commonly in cycles of 4-12 weeks | No human trial establishes this. It is convention among compounding clinics |
| Injection, conservative start | 0.5-1 mg | Once daily for the first week | Tolerance assessment, not an evidence-based figure |
The honest summary of that table is that the topical row rests on a real body of published work and the injectable rows do not. GHK-Cu has been studied extensively for what it does to skin and to gene expression, and barely at all as an injected drug in humans. Anyone quoting a precise injectable protocol is quoting practice, not evidence.
Standard Dosing Protocols
GHK-Cu does not have FDA-approved dosing guidelines as it is classified for research use only. However, studies have explored various dosing regimens, primarily focusing on topical applications due to its role in skin regeneration and wound healing (PMID 35083444, PMID 26236730). Research has typically involved concentrations ranging from 0.1% to 1% in topical formulations, applied once or twice daily.
Topical GHK-Cu: Concentrations Actually Used
Most people searching for GHK-Cu are looking at a serum or cream, where the number that matters is concentration rather than milligrams.
Commercial formulations generally sit between 0.05% and 2%. Below roughly 0.05% there is little reason to expect an effect; above about 2% the main consequence tends to be irritation and, in some formulations, a blue-green tint from the copper itself. Many well-regarded products cluster around 1%.
A practical note on layering: GHK-Cu is a copper complex, and direct-acid vitamin C is often described as destabilising it. Whether this matters at cosmetic concentrations is debated, but the low-cost workaround is simply to use them at different times of day rather than in the same layer.
Topical GHK-Cu does not require the reconstitution arithmetic below, and it is the only route with meaningful published support behind it.[1][2]
Injectable GHK-Cu: What the Evidence Does and Does Not Support
This deserves a direct answer because the search demand is real and the evidence is not.
There is no published human trial that establishes a dose, a frequency, or a cycle length for injected GHK-Cu. The 1-2 mg daily figure that circulates is convention among compounding clinics and peptide vendors. It is not derived from a dose-finding study, because no dose-finding study exists.
What is established is mechanistic and largely preclinical or topical: GHK and GHK-Cu modulate a broad set of genes involved in tissue remodelling, and the peptide's plasma concentration declines substantially with age.[3] That is a plausible rationale for interest. It is not a dosing protocol.
The specific reason to be conservative here is copper. GHK-Cu delivers copper along with the peptide, and copper accumulates. Topical application delivers a negligible systemic amount; repeated injection does not. There is no established safe cumulative injectable dose, which is precisely the figure you would want before running a long protocol.
Reconstituting a 50 mg or 100 mg Vial
Injectable GHK-Cu is usually supplied as a lyophilised powder in 50 mg or 100 mg vials, which is a large amount relative to a 1-2 mg dose. That mismatch is what makes the arithmetic worth doing carefully.
On a U-100 insulin syringe, 100 units is 1 mL. Concentration is vial strength divided by diluent volume; units to draw is dose divided by concentration, times 100.
| Vial | Bacteriostatic water | Concentration | 1 mg dose | 2 mg dose |
|---|---|---|---|---|
| 50 mg | 2.5 mL | 20 mg/mL | 5 units | 10 units |
| 50 mg | 5.0 mL | 10 mg/mL | 10 units | 20 units |
| 100 mg | 3.0 mL | 33.3 mg/mL | 3 units | 6 units |
| 100 mg | 5.0 mL | 20 mg/mL | 5 units | 10 units |
| 100 mg | 10.0 mL | 10 mg/mL | 10 units | 20 units |
Read the top rows carefully. A 100 mg vial in 3 mL puts a 1 mg dose at three units on the syringe — a range where a half-unit misread is a 17% dose error. Diluting the same vial into 10 mL moves that dose to ten units, where the same physical error matters far less. Where a vial holds fifty or a hundred doses, there is no good reason to concentrate it.
The peptide reconstitution calculator and the BAC water calculator will do this arithmetic, and the units converter handles millilitre-to-unit conversion.
Reconstitute by directing the water down the vial wall rather than onto the powder, and swirl rather than shake.
Where to Inject GHK-Cu
Subcutaneous injection sites for GHK-Cu are the same as for other subcutaneously administered peptides: the abdomen at least two inches from the navel, the outer thigh, or the upper outer buttock. Sites should be rotated so that no single area is used repeatedly.
Where GHK-Cu differs from most peptides is that people frequently inject near an area they want to affect, on the assumption that a local injection produces a local effect. That assumption is not well supported. Subcutaneous administration is systemic, and there is no evidence that site selection localises the result. The reason to rotate sites is to avoid irritation and tissue changes, not to target a body area.
Injection site reactions — redness, itching, a small welt — are the most commonly reported adverse effect, and they are more frequent with more concentrated preparations, which is a second argument for generous dilution.
Titration Schedules
Titration of GHK-Cu dosage is essential to balance efficacy with tolerability. Starting with lower concentrations and gradually increasing allows for monitoring of skin response and potential side effects. Clinical protocols often begin with a 0.1% concentration, increasing to 0.5% or 1% as tolerated over several weeks.
Administration Method
GHK-Cu is primarily administered topically. It is applied to clean, dry skin, typically on the face or areas requiring treatment. Storage conditions should be adhered to, keeping the peptide in a cool, dry place to maintain stability. Reconstitution is not applicable for topical formulations, but attention to expiration dates and proper application techniques is crucial.
Factors That Affect Dosing
Individual factors such as body weight, specific treatment goals, concurrent medications, and liver or kidney function can influence GHK-Cu dosing. A healthcare provider will adjust dosing based on these variables to optimize therapeutic outcomes while minimizing risks.
What Happens If You Miss a Dose
If a dose of GHK-Cu is missed, it is generally advised to apply the missed dose as soon as remembered unless it is close to the time for the next application. Doubling up on doses is not recommended to avoid potential skin irritation.
